Concepedia

Jared Gollob

JG

61

Publications

12K

Citations

40

H-Index

1995

Active since

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Dana-Farber Cancer Institute

Beth Israel Deaconess Medical Center

Harvard University

Umeå University

Jared Gollob is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, immunology, and oncology.

ORCID

Top concepts

Publications per year

1995–2023

61

Publications

61

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

Teresa Coelho, David Adams, Ana Silva et al. · New England Journal of Medicine · 2013 · 947 citations · Full text

Impairment of Mycobacterial Immunity in Human Interleukin-12 Receptor Deficiency

Frédéric Altare, Anne Durandy, David A. Lammas et al. · Science · 1998 · 840 citations

, , +14

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

David F. McDermott, Meredith M. Regan, Joseph I. Clark et al. · Journal of Clinical Oncology · 2004 · 814 citations

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso et al. · Cancer Discovery · 2013 · 691 citations

Rows per page

1–5 of 61